Literature DB >> 2127345

Development of quinolone-imipenem cross resistance in Pseudomonas aeruginosa during exposure to ciprofloxacin.

G Rådberg1, L E Nilsson, S Svensson.   

Abstract

Selection and regrowth of ciprofloxacin-resistant variants, which were present in low frequencies in the initial inoculum, were seen when large inocula of Pseudomonas aeruginosa were incubated with ciprofloxacin. These variants showed cross resistance to other quinolones. In 8 of 13 strains tested, ciprofloxacin selected imipenem-resistant variants in a similar way to imipenem. The opposite phenomenon of ciprofloxacin-imipenem cross resistance after exposure to imipenem was not detected. None of the ciprofloxacin-resistant variants showed cross resistance to aztreonam, piperacillin, or tobramycin. These findings indicate that widespread and uncritical use of ciprofloxacin gives a potential risk of development of resistance in P. aeruginosa not only to quinolones but also to another unrelated useful agent, imipenem. In vitro evaluation of this phenomenon in isolates from patients with P. aeruginosa infections may be justified, since strains differ in development of quinolone-imipenem cross resistance after ciprofloxacin exposure.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2127345      PMCID: PMC172014          DOI: 10.1128/AAC.34.11.2142

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Outer membrane alterations in multiresistant mutants of Pseudomonas aeruginosa selected by ciprofloxacin.

Authors:  N J Legakis; L S Tzouvelekis; A Makris; H Kotsifaki
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

2.  Alterations in outer membrane proteins of Pseudomonas aeruginosa associated with selective resistance to quinolones.

Authors:  G L Daikos; V T Lolans; G G Jackson
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

3.  Mechanism of ciprofloxacin resistance in Pseudomonas aeruginosa.

Authors:  G W Kaatz; S M Seo
Journal:  J Infect Dis       Date:  1988-09       Impact factor: 5.226

4.  Quinolone/ureidopenicillin cross-resistance.

Authors:  L J Piddock; W J Wijnands; R Wise
Journal:  Lancet       Date:  1987-10-17       Impact factor: 79.321

5.  Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.

Authors:  A L Barry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

6.  In-vitro selection of bacteria resistant to the 4-quinolone agents.

Authors:  D I Limb; D J Dabbs; R C Spencer
Journal:  J Antimicrob Chemother       Date:  1987-01       Impact factor: 5.790

7.  Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes.

Authors:  C C Sanders; W E Sanders; R V Goering; V Werner
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

8.  Comparative evaluation of recently developed quinolone compounds--with a note on the frequency of resistant mutants.

Authors:  W Cullmann; M Stieglitz; B Baars; W Opferkuch
Journal:  Chemotherapy       Date:  1985       Impact factor: 2.544

9.  Genetic and physiological characterization of ciprofloxacin resistance in Pseudomonas aeruginosa PAO.

Authors:  N J Robillard; A L Scarpa
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

10.  Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis.

Authors:  M Michéa-Hamzehpour; R Auckenthaler; P Regamey; J C Pechère
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

View more
  22 in total

1.  Optimal use of antibiotics for intubation-associated pneumonia.

Authors:  J Rello; E Diaz
Journal:  Intensive Care Med       Date:  2001-02       Impact factor: 17.440

2.  Development of resistance to ciprofloxacin in nutrient-rich and nutrient-limited growth conditions in vitro by Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  M I Ferguson; E M Scott; P S Collier
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

3.  Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa.

Authors:  H Mouneimné; J Robert; V Jarlier; E Cambau
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

Review 4.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

5.  Role of protein D2 and lipopolysaccharide in diffusion of quinolones through the outer membrane of Pseudomonas aeruginosa.

Authors:  M Michéa-Hamzehpour; Y X Furet; J C Pechère
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

Review 6.  Antibacterial treatment of invasive mechanical ventilation-associated pneumonia.

Authors:  F Barcenilla; E Gascó; J Rello; L Alvarez-Rocha
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

7.  Expression of the multidrug resistance operon mexA-mexB-oprM in Pseudomonas aeruginosa: mexR encodes a regulator of operon expression.

Authors:  K Poole; K Tetro; Q Zhao; S Neshat; D E Heinrichs; N Bianco
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

Review 8.  Use of the quinolones in paediatrics.

Authors:  U B Schaad
Journal:  Drugs       Date:  1993       Impact factor: 9.546

9.  Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus.

Authors:  J Fung-Tomc; B Kolek; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

10.  Nosocomial acquisition of Pseudomonas aeruginosa resistant to both ciprofloxacin and imipenem: a risk factor and laboratory analysis.

Authors:  M R Mueller; M K Hayden; S K Fridkin; D K Warren; L Phillips; K Lolans; J P Quinn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-02-26       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.